Camurus AB (PK)【CAMRF】銘柄情報

Camurus AB (PK) (CAMRF) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

59.70

( - )

買値

36.08

売値

83.60

出来高

0.00 日の範囲 0.00

55.00 52 週間の範囲 71.00

時価総額

3.567B

前日終値

59.70

始値

時刻

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

US$ 120,804

発行済株式数

59,749,184

配当利回り

PER

1 株当たり利益 (EPS)

11.35

歳入

2.24B

純利益

682.13M

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixad... Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and is under phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 for the treatment of pulmonary arterial hypertension, as well as in phase II clinical trial to treat Raynaud’s phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM2056 that is in phase I clinical trials for the treatment of metabolic diseases; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity; Gubra A/S to develop long-acting therapeutic option for the treatment of hypoparathyroidism; NewBridge Pharmaceuticals; and Eli Lilly for the development of long-acting incretin medicines based on FluidCrystal technology. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.camurus.com

本社

Lund, Sweden

設立

1991

Camurus AB (PK) is listed in the Healthcare sector of the その他OTC with ticker CAMRF. The last closing price for Camurus AB (PK) was US$59.70. Over the last year, Camurus AB (PK) shares have traded in a share price range of US$ 55.00 to US$ 71.00.

Camurus AB (PK) currently has 59,749,184 shares in issue. The market capitalisation of Camurus AB (PK) is US$3.57 billion. Camurus AB (PK) has a price to earnings ratio (PE ratio) of 48.00.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	59.7	59.7	59.7	100	59.7	CS
4	0	0	59.7	59.7	59.7	100	59.7	CS
12	-3.6	-5.68720379147	63.3	63.3	59.7	60	62.1	CS
26	-4.525	-7.04554301285	64.225	71	55	93	63.11140759	CS
52	-3.3	-5.2380952381	63	71	55	97	64.70674423	CS
156	9.02	17.7979479084	50.68	71.07	46.15	130	60.89929233	CS
260	46.8	362.790697674	12.9	71.07	12.9	119	60.37105865	CS